Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus

cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

Tatiana E. Suslova, Alexei V. Sitozhevskii, Oksana N. Ogurkova, Elena S. Kravchenko, Irina V. Kologrivova, Yana Anfinogenova, Rostislav S. Karpov

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.

Original languageEnglish
Article number501
JournalFrontiers in Physiology
Volume6
Issue numberJAN
DOIs
Publication statusPublished - 2015

Fingerprint

Hemostasis
Platelet Aggregation
Type 2 Diabetes Mellitus
Nitric Oxide
Blood Platelets
Insulin
Cytokines
Nitric Oxide Synthase
Insulin Resistance
Inflammation
Hyperhomocysteinemia
Insulin Receptor
Platelet Activation
Homocysteine
Microcirculation
Dyslipidemias
Glycosylation
Hyperglycemia
Smooth Muscle Myocytes
Accidents

Keywords

  • Cyclic guanosine monophosphate
  • Metabolic syndrome
  • Nitric oxide
  • Nitric oxide synthase
  • Platelets
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus : cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. / Suslova, Tatiana E.; Sitozhevskii, Alexei V.; Ogurkova, Oksana N.; Kravchenko, Elena S.; Kologrivova, Irina V.; Anfinogenova, Yana; Karpov, Rostislav S.

In: Frontiers in Physiology, Vol. 6, No. JAN, 501, 2015.

Research output: Contribution to journalReview article

Suslova, Tatiana E. ; Sitozhevskii, Alexei V. ; Ogurkova, Oksana N. ; Kravchenko, Elena S. ; Kologrivova, Irina V. ; Anfinogenova, Yana ; Karpov, Rostislav S. / Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus : cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. In: Frontiers in Physiology. 2015 ; Vol. 6, No. JAN.
@article{bfed8a34b0b6464b827fc00916a3e976,
title = "Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation",
abstract = "Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.",
keywords = "Cyclic guanosine monophosphate, Metabolic syndrome, Nitric oxide, Nitric oxide synthase, Platelets, Type 2 diabetes mellitus",
author = "Suslova, {Tatiana E.} and Sitozhevskii, {Alexei V.} and Ogurkova, {Oksana N.} and Kravchenko, {Elena S.} and Kologrivova, {Irina V.} and Yana Anfinogenova and Karpov, {Rostislav S.}",
year = "2015",
doi = "10.3389/fphys.2014.00501",
language = "English",
volume = "6",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "JAN",

}

TY - JOUR

T1 - Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus

T2 - cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation

AU - Suslova, Tatiana E.

AU - Sitozhevskii, Alexei V.

AU - Ogurkova, Oksana N.

AU - Kravchenko, Elena S.

AU - Kologrivova, Irina V.

AU - Anfinogenova, Yana

AU - Karpov, Rostislav S.

PY - 2015

Y1 - 2015

N2 - Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.

AB - Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated.

KW - Cyclic guanosine monophosphate

KW - Metabolic syndrome

KW - Nitric oxide

KW - Nitric oxide synthase

KW - Platelets

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84926432380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926432380&partnerID=8YFLogxK

U2 - 10.3389/fphys.2014.00501

DO - 10.3389/fphys.2014.00501

M3 - Review article

VL - 6

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - JAN

M1 - 501

ER -